Appeal 2007-0532
Application 10/828,316
bone marrow cells, mesenchymal stem cells, . . . autogenous
tissues such as blood, serum, . . . human growth hormone
(HGH); . . . transforming growth factor (TGF-beta); insulin-like
growth factor (IGF-1); platelet derived growth factors (PDGF);
fibroblast growth factors (FGF, bFGF, etc.), . . . [and]
somatotropin.”
(Col. 9, ll. 31-62).
Finally, Boyce discloses that the bone particle-containing composition
can be fabricated by wetting a quantity of bone particles with a wetting agent
“to form a composition having the consistency of a slurry or paste.
Optionally, the wetting agent can comprise dissolved or admixed therein one
or more biocompatible substances such as biocompatible binders, fillers,
plasticizers, biostatic/biocidal agents, surface active agents, bioactive
substances, etc., as previously described” (col. 10, ll. 20-30).
Breitbart discloses a method of obtaining cells from periosteum (the
covering around the surface of the bone) and seeding them onto a matrix for
repair of a bone defect (col. 3, ll. 24-26). Breitbart discloses that hydrogel
matrices can be used (col. 3, ll. 34-35) and that the matrix can be formed
from alginate (col. 6, ll. 19-38), optionally stabilized with a polycation such
as chitosan (col. 11, ll. 27-37).
Sander discloses a bone repair composition comprising a matrix
having biocompatible particles dispersed in it (col. 2, ll. 1-4). The
biocompatible particles can be bone particles (col. 4, ll. 12-15), preferably
with an average size of 0.1 to 3 mm (i.e., 100 to 3000 microns) but “even as
small as about 100 to 700 microns” (col. 4, ll. 33-38). Sander also teaches
incorporating growth promoting factors such as FGF or PDGF into the bone
repair composition (col. 4, l. 51 to col. 5, l. 5).
7
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: September 9, 2013